Published in:
01-04-2010 | Research Article
Effect of Prophylactic Dalteparin on Anti-factor Xa Levels in Morbidly Obese Patients After Bariatric Surgery
Published in: Obesity Surgery | Issue 4/2010
Login to get accessAbstract
Background
There are limited data on appropriate dosing of low-molecular-weight heparins (LMWH) for venous thromboembolism (VTE) prophylaxis in bariatric surgery. The objective of this study was to describe the postoperative effects of LMWH dalteparin on anti-factor Xa (AFXa) level in morbidly obese patients undergoing bariatric surgery.
Methods
This was a retrospective study. Morbidly obese patients (BMI ≥ 40 kg/m2 or BMI > 35 kg/m2 with at least one significant co-morbidity) received subcutaneous dalteparin 7,500 IU daily during the postoperative period after biliopancreatic derivation with duodenal switch. AFXa level was measured 4 h after the fourth dalteparin administration.
Results
One hundred and thirty-five patients with a mean BMI of 53.7 kg/m2 were included into this study. Only 60% of patients had targeted AFXa levels (0.2–0.5 UI/ml). There was a statistical difference in body weight between individuals with sub-target AFXa levels and those with values over target (159.4 ± 35.8 vs. 134.6 ± 24.2, p = 0.0310). There were three haemorrhages documented. These events were not associated with elevated AFXa values.
Conclusion
These findings indicate that the 7,500 IU dalteparin dosage is appropriate for the majority of morbidly obese patients undergoing bariatric surgery. The present study, however, suggests that this dose might not be sufficient for patient with a very high body weight.